Hosted on MSN1mon
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary GoalsIL-5 is present at high levels in nasal polyp tissue. IL-5 inhibitors play a key role in reducing type II inflammation. Year to date, shares of GSK have risen 5.5% against the industry’s decline ...
IL-5 is present at high levels in nasal polyp tissue. IL-5 inhibitors play a key role in reducing type II inflammation. Year to date, shares of GSK have risen 5.5% against the industry’s decline ...
Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...
Drugmaker GSK shared positive results Monday from two Phase 3 trials testing its inflammatory disease drug depemokimab in people with a condition known as chronic rhinosinusitis with nasal polyps.
UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback